NO933972L - Fremgangsmaete for fremstilling av 3 -hydroksy, 3 -substituerte pregnaner - Google Patents

Fremgangsmaete for fremstilling av 3 -hydroksy, 3 -substituerte pregnaner

Info

Publication number: NO933972L
Authority: NO; Norway
Prior art keywords: hydroxy; substituted; pregnants; procedure; preparation
Prior art date: 1992-03-04

Application number

NO933972A

Other languages

English (en)

Other versions

NO933972D0 (no

NO305604B1 (no

Inventor

Syed Hasan Tahir

Michael Bruce Bolger

Richard Buswell

Richard Gabriel

Jay Stearns

Original Assignee

Cocensys Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-03-04

Filing date

1993-11-03

Publication date

1993-11-03

1993-11-03 Application filed by Cocensys Inc filed Critical Cocensys Inc

1993-11-03 Publication of NO933972D0 publication Critical patent/NO933972D0/no

1993-11-03 Publication of NO933972L publication Critical patent/NO933972L/no

1999-06-28 Publication of NO305604B1 publication Critical patent/NO305604B1/no

Links

238000000034 method Methods 0.000 title abstract 3
208000032749 Pregnancy Diseases 0.000 title 1
XMRPGKVKISIQBV-CVHNGYJVSA-N 5-α-pregnan-3,20-dione Chemical class C1CC2CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 XMRPGKVKISIQBV-CVHNGYJVSA-N 0.000 abstract 1
238000006243 chemical reaction Methods 0.000 abstract 1
239000003153 chemical reaction reagent Substances 0.000 abstract 1
125000000468 ketone group Chemical group 0.000 abstract 1
150000002576 ketones Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
- C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
- C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
- C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Steroid Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Diaphragms For Electromechanical Transducers (AREA)
External Artificial Organs (AREA)
Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Detergent Compositions (AREA)

NO933972A 1992-03-04 1993-11-03 FremgangsmÕte for fremstilling av 3<alfa>-hydroksy-3<beta>-substituert-5<alfa>- pregnan-20-on-forbindelser NO305604B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US07/846,193 US5319115A (en)	1987-08-25	1992-03-04	Method for making 3α-hydroxy, 3β-substituted-pregnanes
PCT/US1993/001602 WO1993018053A1 (en)	1992-03-04	1993-02-22	METHOD FOR MAKING 3α-HYDROXY,3β-SUBSTITUTED-PREGNANES

Publications (3)

Publication Number	Publication Date
NO933972D0 NO933972D0 (no)	1993-11-03
NO933972L true NO933972L (no)	1993-11-03
NO305604B1 NO305604B1 (no)	1999-06-28

Family

ID=25297208

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO933972A NO305604B1 (no)	1992-03-04	1993-11-03	FremgangsmÕte for fremstilling av 3<alfa>-hydroksy-3<beta>-substituert-5<alfa>- pregnan-20-on-forbindelser

Country Status (14)

Country	Link
US (1)	US5319115A (no)
EP (1)	EP0589034B1 (no)
JP (2)	JP3983796B2 (no)
KR (1)	KR100257031B1 (no)
AT (1)	ATE179715T1 (no)
AU (1)	AU668926B2 (no)
CA (1)	CA2102400C (no)
DE (1)	DE69324752T2 (no)
DK (1)	DK0589034T3 (no)
ES (1)	ES2132249T3 (no)
FI (1)	FI111843B (no)
GR (1)	GR3030660T3 (no)
NO (1)	NO305604B1 (no)
WO (1)	WO1993018053A1 (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5232917A (en) *	1987-08-25	1993-08-03	University Of Southern California	Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5939545A (en) *	1994-02-14	1999-08-17	Cocensys, Inc.	Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
ATE284895T1 (de) *	1995-06-06	2005-01-15	Euro Celtique Sa	Neuroaktive steroide der androstan- und pregnanreihe
US6780853B1 (en)	1995-06-06	2004-08-24	Euro-Celtique S.A.	Neuroactive steroids of the androstane and pregnane series
UA73736C2 (en) *	1999-04-29	2005-09-15	Euro Celtic S A	Method for alleviating or preventing insomnia and inducing anesthesia
EP2258358A3 (en)	2005-08-26	2011-09-07	Braincells, Inc.	Neurogenesis with acetylcholinesterase inhibitor
EP2275095A3 (en)	2005-08-26	2011-08-17	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation
EP1940389A2 (en)	2005-10-21	2008-07-09	Braincells, Inc.	Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en)	2005-10-31	2007-05-10	Braincells, Inc.	GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
EP2382975A3 (en)	2006-05-09	2012-02-29	Braincells, Inc.	Neurogenesis by modulating angiotensin
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
CN102549007B (zh)	2009-08-13	2015-03-18	马瑞纳斯制药公司	3α-羟基,3β-甲基-5α-孕烷-20-酮(加奈索酮)的制备方法
EP3572417B1 (en)	2011-10-14	2025-12-17	Sage Therapeutics, LLC	3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
EP2806877B2 (en)	2012-01-23	2025-01-29	Sage Therapeutics, Inc.	Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin
CA2882708A1 (en)	2012-08-21	2014-02-27	Sage Therapeutics, Inc.	Methods of treating epilepsy or status epilepticus
AU2013352141B2 (en)	2012-11-30	2018-04-05	The Regents Of The University Of California	Anticonvulsant activity of steroids
US9725481B2 (en)	2013-04-17	2017-08-08	Sage Therapeutics, Inc.	19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
KR102396328B1 (ko)	2013-04-17	2022-05-10	세이지 테라퓨틱스, 인크.	19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
EP2986624B1 (en)	2013-04-17	2020-03-25	Sage Therapeutics, Inc.	19-nor neuroactive steroids for methods of treatment
US20160068563A1 (en)	2013-04-17	2016-03-10	Boyd L. Harrison	19-nor neuroactive steroids and methods of use thereof
SI3021852T1 (sl)	2013-07-19	2021-07-30	Sage Therapeutics, Inc.	Nevroaktivni steroidi, sestavki in uporabe le-teh
AU2014308621C1 (en)	2013-08-23	2022-01-06	Sage Therapeutics, Inc.	Neuroactive steroids, compositions, and uses thereof
US9629853B2 (en)	2014-05-21	2017-04-25	Wisconsin Alumni Research Foundation	Uses of ganaxolone
US10246482B2 (en)	2014-06-18	2019-04-02	Sage Therapeutics, Inc.	Neuroactive steroids, compositions, and uses thereof
WO2016036724A1 (en)	2014-09-02	2016-03-10	The Texas A&M University System	Method of treating organophosphate intoxication
JOP20200195A1 (ar)	2014-09-08	2017-06-16	Sage Therapeutics Inc	سترويدات وتركيبات نشطة عصبياً، واستخداماتها
ME03809B (me)	2014-10-16	2021-04-20	Sage Therapeutics Inc	KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a
CN117024501A (zh)	2014-10-16	2023-11-10	萨奇治疗股份有限公司	靶向cns障碍的组合物和方法
WO2016082789A1 (en)	2014-11-27	2016-06-02	Sage Therapeutics, Inc.	Compositions and methods for treating cns disorders
RS61530B1 (sr)	2015-01-26	2021-04-29	Sage Therapeutics Inc	Kompozicije i postupci za lečenje poremećaja cns
EP4155314A1 (en)	2015-02-20	2023-03-29	Sage Therapeutics, Inc.	Neuroactive steroids, compositions, and uses thereof
KR20240157128A (ko)	2016-03-08	2024-10-31	세이지 테라퓨틱스, 인크.	신경활성 스테로이드, 조성물, 및 그의 용도
MA45599A (fr)	2016-07-11	2019-05-15	Sage Therapeutics Inc	Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
WO2018013615A1 (en)	2016-07-11	2018-01-18	Sage Therapeutics, Inc.	C7, c12, and c16 substituted neuroactive steroids and their methods of use
SG11202112391UA (en)	2019-05-31	2021-12-30	Sage Therapeutics Inc	Neuroactive steroids and compositions thereof
WO2023060067A1 (en)	2021-10-04	2023-04-13	Marinus Pharmaceuticals, Inc.	Amorphous solid dispersion ganaxolone formulation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3600412A (en) *	1965-03-24	1971-08-17	Upjohn Co	6,1'-spirocyclopropyl compounds of the androstane series
US3466276A (en) *	1967-09-05	1969-09-09	Upjohn Co	2-piperidylglycol ketals of steroidal compounds
US3697509A (en) *	1970-04-13	1972-10-10	Searle & Co	N-(3-oxopregna-4, 17(20)-dien-21-yl) quaternary salts and }9-nor derivatives corresponding
US3953429A (en) *	1970-12-17	1976-04-27	Glaxo Laboratories Limited	Anaesthetic steroids of the androstance and pregnane series
DE2237143A1 (de) *	1972-07-28	1974-02-14	Hoechst Ag	Verfahren zur herstellung von beta(3-keto-7alpha-acetylthio-17beta-hydroxy4-androsten-17alpha-yl)-propionsaeuregamma-lacton und dessen 1-dehydro-derivat
ZA8231B (en) *	1981-01-09	1982-11-24	Roussel Uclaf	New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
DE3373189D1 (en) *	1982-06-21	1987-10-01	Dainippon Ink & Chemicals	Process for preparation of steroids
DE3227312A1 (de) *	1982-07-19	1984-01-19	Schering AG, 1000 Berlin und 4709 Bergkamen	Neue 6,16-dimethylkortikoide, ihre herstellung und verwendung
US4501695A (en) *	1983-05-16	1985-02-26	The Upjohn Company	Spironalactone process
US4613463A (en) *	1984-11-01	1986-09-23	The Upjohn Company	Process and intermediates for the preparation of 17 alphahydroxyprogesterones and corticoids from an enol steroid
US5034548A (en) *	1987-01-30	1991-07-23	E. I. Du Pont De Nemours And Company	Steroid derivatives useful as hypocholesterolemics
US5120723A (en) *	1987-08-25	1992-06-09	University Of Southern California	Method, compositions, and compounds for modulating brain excitability
US5232917A (en) *	1987-08-25	1993-08-03	University Of Southern California	Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
FR2644788B1 (fr) *	1989-03-22	1995-02-03	Roussel Uclaf	Nouveaux steroides 3-ceto comportant une chaine en 17 amino-substituee, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant

1992
- 1992-03-04 US US07/846,193 patent/US5319115A/en not_active Expired - Lifetime
1993
- 1993-02-22 EP EP93918762A patent/EP0589034B1/en not_active Expired - Lifetime
- 1993-02-22 AT AT93918762T patent/ATE179715T1/de active
- 1993-02-22 DK DK93918762T patent/DK0589034T3/da active
- 1993-02-22 WO PCT/US1993/001602 patent/WO1993018053A1/en not_active Ceased
- 1993-02-22 AU AU37758/93A patent/AU668926B2/en not_active Expired
- 1993-02-22 CA CA002102400A patent/CA2102400C/en not_active Expired - Lifetime
- 1993-02-22 DE DE69324752T patent/DE69324752T2/de not_active Expired - Lifetime
- 1993-02-22 KR KR1019930703325A patent/KR100257031B1/ko not_active Expired - Lifetime
- 1993-02-22 ES ES93918762T patent/ES2132249T3/es not_active Expired - Lifetime
- 1993-02-22 JP JP51572793A patent/JP3983796B2/ja not_active Expired - Lifetime
- 1993-11-03 NO NO933972A patent/NO305604B1/no not_active IP Right Cessation
- 1993-11-03 FI FI934861A patent/FI111843B/fi not_active IP Right Cessation
1999
- 1999-06-30 GR GR990401746T patent/GR3030660T3/el unknown
2006
- 2006-02-15 JP JP2006038313A patent/JP2006151994A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
NO933972D0 (no)	1993-11-03
ES2132249T3 (es)	1999-08-16
GR3030660T3 (en)	1999-10-29
EP0589034A4 (en)	1996-05-22
EP0589034B1 (en)	1999-05-06
FI111843B (fi)	2003-09-30
JP2006151994A (ja)	2006-06-15
WO1993018053A1 (en)	1993-09-16
DK0589034T3 (da)	1999-11-01
AU668926B2 (en)	1996-05-23
DE69324752T2 (de)	1999-09-09
JP3983796B2 (ja)	2007-09-26
DE69324752D1 (de)	1999-06-10
AU3775893A (en)	1993-10-05
NO305604B1 (no)	1999-06-28
CA2102400A1 (en)	1993-09-05
JPH06507427A (ja)	1994-08-25
CA2102400C (en)	2004-08-10
KR100257031B1 (ko)	2000-08-01
FI934861L (fi)	1993-11-03
FI934861A0 (fi)	1993-11-03
US5319115A (en)	1994-06-07
EP0589034A1 (en)	1994-03-30
ATE179715T1 (de)	1999-05-15

Legal Events

Date	Code	Title	Description
2013-03-11	MK1K	Patent expired

Publication	Publication Date	Title
NO933972L (no)	1993-11-03	Fremgangsmaete for fremstilling av 3 -hydroksy, 3 -substituerte pregnaner
AU6172596A (en)	1996-12-30	Neuroactive steroids of the androstane and pregnane series
DE69433010D1 (de)	2003-09-11	Verfahren zur darstellung von oligonukleotiden
SG6586G (en)	1986-08-01	Monoclonal antibody to human helper t cells, method of preparing it, hybrid cell line producing it, its diagnostic and therapeutic uses and diagnostic and therapeutic composi
ATE225367T1 (de)	2002-10-15	Verfahren zur herstellung von 3-keto-7alpha- alkoxycarbonyl- delta4,5-steroiden sowie zwischenprodukte
DK0582338T3 (da)	2000-03-20	17-spiromethylensteroider
UA6044A1 (uk)	1994-12-29	Спосіб одержання метіленових похідних андроста-1,4 -діен-3,17-діона
ATE165365T1 (de)	1998-05-15	Neue 19-nor steroide, die an der 11-beta stelle an eine thiokohlenstoffgruppe gebunden sind, ein verfahren zu ihrer herstellung und zwischenprodukte dazu
ATE289318T1 (de)	2005-03-15	17alfa, 21-dihydroxypregnene esters als antiandrogene wirkstoffe
DE60030410D1 (de)	2006-10-12	Steroid sulfataseinhibitoren, verfahren zu ihrer herstellung und ihre verwendung
KR900009595A (ko)	1990-07-05	2-클로로-5-클로로메틸피리딘의 제조방법
IL154828A0 (en)	2003-10-31	17alpha FLUOROALKYL STEROIDS, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS
NO302123B1 (no)	1998-01-26	Analogifremgangsmåte for fremstilling av terapeutisk aktive 2<beta>,19-metylenaminobroede steroider
EP1196428A4 (en)	2002-10-16	STEROIDS SUBSTITUTED BY 11-BETA-ARYL-17.17-SPIROTHIOLANE
DK0647235T3 (da)	1997-10-27	Fremgangsmåde til steroide peracylglycosider
DE3577710D1 (de)	1990-06-21	Steroide verbindungen.
PT866798E (pt)	2003-09-30	Preparacao de derivados esterificados de esteroides
岩井重久	1981	A Note on “Anaerobic Digestion and Utilization of Digester Gas”
NO941919L (no)	1994-05-24	Fremgangsmåte for fremstilling av steroide peracylglycosider
BA97185B1 (bs)	1999-08-02	Postupak za dobijanje supstituisanih androsta-1,4-dien-3,17-diona